Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00675233 · ClinicalTrials.gov registry record · Phase 1
Photodynamic Therapy Using HPPH in Treating Patients With Dysplasia, Cancer in Situ, or Invasive Cancer of the Larynx
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT00675233 is a Phase 1 study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 29 participants.
The verdict
NCT00675233, a Phase 1 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
RATIONALE: Photodynamic therapy uses a drug, such as HPPH, that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed. This may be an effective treatment for laryngeal cancer. PURPOSE: This phase I trial is studying the side effects and best dose of laser light therapy when given together with HPPH in treating patients with dysplasia, cancer in situ, or invasive cancer of the larynx.
Interventions
- DRUG HPPH
- PROCEDURE laser therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2008-04-25 |
| Est. Completion | 2018-09-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00675233
The ClinicalTrials.gov registry entry for NCT00675233 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which HPPH is the first listed.
NCT00675233 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00675233 about?
NCT00675233 is a clinical study titled "Photodynamic Therapy Using HPPH in Treating Patients With Dysplasia, Cancer in Situ, or Invasive Cancer of the Larynx". RATIONALE: Photodynamic therapy uses a drug, such as HPPH, that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed. This may be an effective treatment for laryngeal cancer. PURPOSE: This phase I trial is studying the side effects and best d...
What is the current status of trial NCT00675233?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2008-04-25. Estimated completion is 2018-09-27.
What interventions are being tested in trial NCT00675233?
The interventions under investigation include: HPPH (DRUG), laser therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00675233?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.